Trial Profile
Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting PD-L1 and CD80/CD86 (Zeushield Cytotoxic T Lymphocytes) for the Treatment of Recurrent or Refractory Non Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs CAR T cell therapy Hunan Zhaotai Yongren Biotech/Hunan Yongren Medical Innovation (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- 08 Mar 2017 New trial record